CN109415313B - 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物 - Google Patents
新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物 Download PDFInfo
- Publication number
- CN109415313B CN109415313B CN201680087228.6A CN201680087228A CN109415313B CN 109415313 B CN109415313 B CN 109415313B CN 201680087228 A CN201680087228 A CN 201680087228A CN 109415313 B CN109415313 B CN 109415313B
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyl
- alkyl
- err
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (3)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160080124A KR101819639B1 (ko) | 2016-06-27 | 2016-06-27 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
KR10-2016-0080124 | 2016-06-27 | ||
PCT/KR2016/010364 WO2018004065A1 (ko) | 2016-06-27 | 2016-09-13 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109415313A CN109415313A (zh) | 2019-03-01 |
CN109415313B true CN109415313B (zh) | 2022-08-26 |
Family
ID=60786977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680087228.6A Active CN109415313B (zh) | 2016-06-27 | 2016-09-13 | 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10934303B2 (zh) |
EP (1) | EP3480186B1 (zh) |
KR (1) | KR101819639B1 (zh) |
CN (1) | CN109415313B (zh) |
ES (1) | ES2925102T3 (zh) |
WO (1) | WO2018004065A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11413270B2 (en) * | 2020-06-22 | 2022-08-16 | Novmetapharma Co., Ltd. | Method for the treatment of pancreatitis |
US11850246B2 (en) | 2020-08-04 | 2023-12-26 | Novmetapharma Co., Ltd. | Method for treatment of cytokine release syndrome |
KR20230074982A (ko) | 2021-11-22 | 2023-05-31 | 주식회사 노브메타파마 | 아릴에텐 화합물의 제조방법 |
KR20230146812A (ko) * | 2022-04-13 | 2023-10-20 | 재단법인 대구경북첨단의료산업진흥재단 | 아릴에텐 유도체를 유효성분으로 포함하는 염증성 장질환 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4996225A (en) * | 1982-06-25 | 1991-02-26 | Farmos Group Ltd. | Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses |
CN1399622A (zh) * | 1999-11-16 | 2003-02-26 | 霍尔莫斯医疗有限公司 | 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途 |
CN101360488A (zh) * | 2005-11-22 | 2009-02-04 | 史密丝克莱恩比彻姆公司 | 化合物 |
KR20150035432A (ko) * | 2013-09-25 | 2015-04-06 | 경북대학교 산학협력단 | ERR-γ 저해제를 포함하는, 망막병증의 예방 또는 치료용 약학적 조성물 및 이의 용도 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI77839C (fi) * | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
-
2016
- 2016-06-27 KR KR1020160080124A patent/KR101819639B1/ko active IP Right Grant
- 2016-09-13 ES ES16907430T patent/ES2925102T3/es active Active
- 2016-09-13 WO PCT/KR2016/010364 patent/WO2018004065A1/ko unknown
- 2016-09-13 EP EP16907430.9A patent/EP3480186B1/en active Active
- 2016-09-13 US US16/313,351 patent/US10934303B2/en active Active
- 2016-09-13 CN CN201680087228.6A patent/CN109415313B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4996225A (en) * | 1982-06-25 | 1991-02-26 | Farmos Group Ltd. | Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses |
CN1399622A (zh) * | 1999-11-16 | 2003-02-26 | 霍尔莫斯医疗有限公司 | 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途 |
CN101360488A (zh) * | 2005-11-22 | 2009-02-04 | 史密丝克莱恩比彻姆公司 | 化合物 |
KR20150035432A (ko) * | 2013-09-25 | 2015-04-06 | 경북대학교 산학협력단 | ERR-γ 저해제를 포함하는, 망막병증의 예방 또는 치료용 약학적 조성물 및 이의 용도 |
Non-Patent Citations (3)
Title |
---|
Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues;Khaled R. A. Abdellatif, et al;《Bioorganic Medicinal Chemistry Letters》;20130626;第23卷;第4960-4963页 * |
Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells;Thoudam Debraj Singh, et al;《The Journal Of Nuclear Medicine》;20151130;第56卷(第11期);第1690-1696页 * |
Synthesis and biological evaluation of novel 4-hydroxytamoxifen analogs as estrogen-related receptor gamma inverse agonists;Jina Kim, et al;《European Journal of Medicinal Chemistry》;20160509;第120卷;第338-352页 * |
Also Published As
Publication number | Publication date |
---|---|
KR20180001240A (ko) | 2018-01-04 |
US10934303B2 (en) | 2021-03-02 |
WO2018004065A1 (ko) | 2018-01-04 |
EP3480186A1 (en) | 2019-05-08 |
ES2925102T3 (es) | 2022-10-13 |
KR101819639B1 (ko) | 2018-01-17 |
EP3480186B1 (en) | 2022-06-15 |
EP3480186A4 (en) | 2020-03-11 |
CN109415313A (zh) | 2019-03-01 |
US20190161490A1 (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107406424B (zh) | 雌激素受体调节剂及其用途 | |
CN109415313B (zh) | 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物 | |
JP5442906B2 (ja) | キナーゼインヒビターおよびこれを用いた癌の治療方法 | |
WO2020063792A1 (zh) | 吲哚类大环衍生物、其制备方法及其在医药上的应用 | |
CN112457310A (zh) | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 | |
JP6689856B2 (ja) | 6,7−ジヒドロピラゾロ[1,5−a]ピラジン−4(5H)−オン化合物およびMGLUR2受容体の負のアロステリック調節因子としてのそれらの使用 | |
JP5800814B2 (ja) | 複素環化合物およびその用途 | |
TW201215611A (en) | Tetrahydrocarboline derivative | |
TW201708195A (zh) | 用於治療脫髓鞘疾病之三唑 | |
AU2012328763A1 (en) | Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo(d)imidazol-2-yl)-1H-pyrazole-4-carboxylic acid | |
CN109071548A (zh) | 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物 | |
JP2020529439A (ja) | ジヒドロオキサジアジノン | |
CN110325523B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
CN109563054B (zh) | 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物 | |
KR101835133B1 (ko) | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
WO2022098970A1 (en) | Pyrazole derivatives asr et kinase inhibitors | |
AU2019363148A1 (en) | Urea derivatives for treating and/or preventing cancer | |
KR20180001405A (ko) | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
JP6921100B2 (ja) | 複素環化合物 | |
WO2023215449A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
CN115916196A (zh) | 杂芳族大环醚化学治疗剂 | |
TW202108576A (zh) | 用於治療hbv感染或hbv誘發的疾病之醯胺衍生物 | |
CN104936957A (zh) | 二肽基肽酶抑制剂 | |
TW201317239A (zh) | 經羥甲基芳基-取代之吡咯並三□及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201201 Address after: Han Guodaqiu Applicant after: Daegu-Gyeongbuk Medical Innovation Foundation Applicant after: Qingbei National University Hospital Applicant after: Qingbei University School Industry University Cooperative Force Address before: Han Guoqingshangbeidao Applicant before: KEMIMEDI Co.,Ltd. Applicant before: Huang Chengyuan |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220119 Address after: Seoul, South Kerean Applicant after: Metabolic health Address before: Daegu, Korea Applicant before: Daegu-Gyeongbuk Medical Innovation Foundation Applicant before: Qingbei National University Hospital Applicant before: Qingbei University School Industry University Cooperative Force |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220812 Address after: Seoul, South Kerean Applicant after: Nometa Pharmaceutical Co.,Ltd. Address before: Seoul, South Kerean Applicant before: Metabolic health |
|
TA01 | Transfer of patent application right |